Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
Industry, Sector and Symbol:
- Market Cap: $4.06 million
- Outstanding Shares: 740,000
- 50 Day Moving Avg: $5.51
- 200 Day Moving Avg: $6.77
- 52 Week Range: $4.52 - $49.41
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.05
- P/E Growth: 0.01
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($4.06) per share
- Price / Book: -1.35
- EBIDTA: ($5,090,000.00)
- Return on Equity: -101.88%
- Return on Assets: -87.37%
- Current Ratio: 10.64%
- Quick Ratio: 10.63%
- Average Volume: 21,218 shs.
- Beta: 0.84
- Short Ratio: 4.22
Frequently Asked Questions for Tokai Pharmaceuticals (NASDAQ:NVUS)
What is Tokai Pharmaceuticals' stock symbol?
Tokai Pharmaceuticals trades on the NASDAQ under the ticker symbol "NVUS."
How were Tokai Pharmaceuticals' earnings last quarter?
Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) issued its earnings results on Tuesday, May, 10th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.01. View Tokai Pharmaceuticals' Earnings History.
Where is Tokai Pharmaceuticals' stock going? Where will Tokai Pharmaceuticals' stock price be in 2017?
6 brokers have issued twelve-month price objectives for Tokai Pharmaceuticals' shares. Their forecasts range from $1.15 to $1.15. On average, they expect Tokai Pharmaceuticals' stock price to reach $1.15 in the next year. View Analyst Ratings for Tokai Pharmaceuticals.
Who are some of Tokai Pharmaceuticals' key competitors?
Some companies that are related to Tokai Pharmaceuticals include Interpace Diagnostics Group (IDXG), Celsion Corporation (CLSN), Opexa Therapeutics (OPXA), Acura Pharmaceuticals (ACUR), Rosetta Genomics (ROSG), Strata Skin Sciences (SSKN), NeuroMetrix (NURO), Windtree Therapeutics (WINT), Dextera Surgical (DXTR), Critical Outcome T (COTQF), Affymax (AFFY), Adeptus Health (ADPT), Alphatec Holdings (ATEC), Caladrius Biosciences (CLBS), DelMar Pharmaceuticals (DMPI), DNIB Unwind (BIND), Echo Therapeutics (ECTE) and Epirus Biopharmaceuticals (EPRS).
Who are Tokai Pharmaceuticals' key executives?
Tokai Pharmaceuticals' management team includes the folowing people:
- Keith A. Katkin, Chairman of the Board
- Gregory J. Flesher, President, Chief Executive Officer, Director
- Christine Ocampo, Chief Financial Officer, Principal Accounting Officer, Chief Compliance Officer
- Catherine Turkel, Chief Development Officer
- Erez Chimovits, Director
- Cheryl L. Cohen, Director
- Gary A. Lyons, Director
- John S. McBride, Director
- Jodie Pope Morrison, Director
How do I buy Tokai Pharmaceuticals stock?
Shares of Tokai Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tokai Pharmaceuticals' stock price today?
MarketBeat Community Rating for Tokai Pharmaceuticals (NASDAQ NVUS)MarketBeat's community ratings are surveys of what our community members think about Tokai Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Tokai Pharmaceuticals stock can currently be purchased for approximately $5.48.
Consensus Ratings for Tokai Pharmaceuticals (NASDAQ:NVUS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 5 Hold Ratings|
|Consensus Rating:||Hold (Score: 1.83)|
|Consensus Price Target: ||$1.15 (79.01% downside)|
Analysts' Ratings History for Tokai Pharmaceuticals (NASDAQ:NVUS)
(Data available from 7/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/24/2016||BMO Capital Markets||Reiterated Rating||Market Perform||$1.70 -> $1.15||N/A|
|8/10/2016||William Blair||Reiterated Rating||Neutral||N/A|
|7/28/2016||Bank of America Corporation||Downgrade||Neutral -> Underperform||N/A|
|7/26/2016||Stifel Nicolaus||Downgrade||Buy -> Hold||N/A|
|7/26/2016||Janney Montgomery Scott||Downgrade||Buy -> Neutral||N/A|
|7/26/2016||Wells Fargo & Company||Downgrade||Outperform -> Market Perform||N/A|
|2/11/2016||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||N/A|
Earnings History for Tokai Pharmaceuticals (NASDAQ:NVUS)Earnings History by Quarter for Tokai Pharmaceuticals (NASDAQ NVUS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Tokai Pharmaceuticals (NASDAQ:NVUS)
Current Year EPS Consensus Estimate: $-9.99 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS
Dividend History for Tokai Pharmaceuticals (NASDAQ:NVUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tokai Pharmaceuticals (NASDAQ:NVUS)
Insider Ownership Percentage: 39.90%Insider Trades by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)
Institutional Ownership Percentage: 36.94%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/10/2017||Catherine C. Turkel||Insider||Buy||11,111||$9.99||$110,998.89|| |
|5/10/2017||Gregory J. Flesher||CEO||Buy||58,959||$9.99||$589,000.41|| |
|3/15/2016||Stephen Jr. Buckley||Director||Buy||8,000||$5.74||$45,920.00|| |
|11/11/2015||Stephen Jr. Buckley||Director||Buy||3,000||$11.25||$33,750.00|| |
|9/21/2015||John S. Mcbride||COO||Sell||13,500||$14.01||$189,135.00|| |
|9/8/2015||Lee Kalowski||CFO||Sell||4,668||$13.13||$61,290.84|| |
|9/2/2015||Lee Kalowski||CFO||Sell||2,158||$12.96||$27,967.68|| |
|7/15/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||3,566||$14.26||$50,851.16|| |
|7/14/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||27,861||$14.41||$401,477.01|| |
|7/13/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||20,611||$14.20||$292,676.20|| |
|6/29/2015||Jodie Pope Morrison||CEO||Sell||16,000||$13.77||$220,320.00|| |
|6/24/2015||John S Mcbride||COO||Sell||9,000||$14.01||$126,090.00|| |
|6/23/2015||John S Mcbride||COO||Sell||6,700||$14.00||$93,800.00|| |
|6/22/2015||John S Mcbride||COO||Sell||2,000||$14.02||$28,040.00|| |
|6/16/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||1,120||$14.27||$15,982.40|| |
|6/11/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||27,875||$14.20||$395,825.00|| |
|4/16/2015||Lee Kalowski||CFO||Sell||4,567||$13.00||$59,371.00|| |
|4/2/2015||Lee Kalowski||CFO||Sell||2,258||$11.45||$25,854.10|| |
|3/19/2015||Bioventures Ltd Novartis||Major Shareholder||Sell||49,141||$14.50||$712,544.50|| |
|9/22/2014||Apple Tree Partners Ii - Annex||Director||Buy||237,500||$15.00||$3,562,500.00|| |
|9/22/2014||Bioventures Ltd Novartis||Major Shareholder||Buy||325,000||$15.00||$4,875,000.00|| |
Headline Trends for Tokai Pharmaceuticals (NASDAQ:NVUS)
Latest Headlines for Tokai Pharmaceuticals (NASDAQ:NVUS)
Tokai Pharmaceuticals (NVUS) Chart for Monday, July, 24, 2017